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Background: Diabetic nephropathy is a clinical diagnosis where proteinuria is present in a patient with diabetes.
Early intervention can significantly improve the prognosis. However, imprecision of the currently available
biomarkers have impaired effective therapies in a timely manner. Urinary N-acetyl-β-D-glucosaminidase (NAG) is
excreted in abnormally high amounts in many renal diseases. The aim of this study was to evaluate urinary NAG as
an early biomarker in detection of diabetic nephropathy and whether it parallels the severity of kidney damage in
different stages of diabetic nephropathy.
Methods: Fifty patients with type 2 DM were classified into 3 groups (normoalbuminurea, microalbuminurea and
macroalbuminurea) and 10 healthy subjects served as a control group. Urinary NAG, albumin and creatinine were
measured. Blood urea, serum creatinine, serum albumin, total proteins, serum cholesterol, alanine aminotransferase
(ALT), aspartate aminotransferase (AST), fasting and postprandial blood glucose, HbA1c and creatinine clearance
were measured for all subjects.
Results: All diabetic patients had a significantly higher level of urinary NAG compared to control. NAG value
increased in parallel with the severity of renal involvement.
Conclusion: Urinary NAG expresses the degree of renal impairment in diabetic nephropathy.
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Diabetic nephropathy occurs in 20–40% of patients with
diabetes and is the leading cause of chronic kidney dis-
ease and end-stage renal disease [1,2]. The onset of ele-
vated levels of urinary albumin excretion is an early sign
of diabetic nephropathy. It has been shown in diabetic
patients that, microalbuminuria predicts the occurrence
of macroalbuminuria and renal function decline [3]. As
a result, high albuminuria has become an established
renal risk marker in these patients [4]. However, urinary
albumin excretion can be affected by several factors in-
cluding plasma concentrations of atrial natriuretic pep-
tide, arginine vasopressin, angiotensin II, aldosterone and
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unless otherwise stated.arterial blood pressure [5] and albumin can be degraded
in a manner consistent with the activity of endogenous
urinary proteases. Furthermore, the inter-individual vari-
ation is as high as 47%. Because of these problems, all re-
sults that are initially positive for albuminuria need to be
confirmed with a second sample collected on a different
day, and in cases of discrepancies between the first and
second sample, a third sample is necessary [6].
Several tubular damage markers recently have been dis-
covered. Increased levels of these markers are supposed to
indicate proximal tubular damage in the case of kidney in-
jury molecule (KIM)-1, neutrophil gelatinase–associated
lipocalin (NGAL), N-acetyl-β-D glucosaminidase (NAG),
and cystatin C and distal tubular damage in the case of
heart fatty acid–binding protein (H-FABP). These tubular
damage markers have been extensively investigated in the
field of predicting the occurrence of acute kidney injury
after various nephrotoxic insults, such as ischemia duringThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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medium [7,8]. Little research has been done in patients
with chronic kidney disease. In this study, we aimed to in-
vestigate urinary level of the N-acetyl-β-Dglucosaminidase
(NAG) as proximal tubular damage marker in diabetic pa-
tients and non-diabetic control subjects in order to evalu-
ate the relation of this marker to the severity of kidney
disease as assessed by albuminuria and the estimated
glomerular filtration rate (eGFR).
Methods
This study was conducted in the Internal Medicine
Department, Tanta University Hospital from April 2013
to October 2013. After approval of the Institutional
Review Board of the College of Medicine, Tanta Uni-
versity, Egypt, fifty type 2 diabetic patients with initial
diagnosis of diabetes at >30 years of age were recruited
into the study. They were collected from inpatients and
also from outpatients who were followed in the diabetic
clinic. Hospitalized diabetic patients enrolled in our
study were non-critically ill and their samples were not
collected until they had fully recovered from their me-
dical illness. Patients were stratified by the extent of
albuminuria in the first morning urine void. Besides, we
included 10 non diabetic volunteers as controls. Patients
were divided into 4 groups: Group I: 10 non diabetic non
hypertensive healthy persons as a control group, group II:
10 patients with normoalbuminuria, albumin creatinine
ratio (ACR) ≤3 mg/mmol), group III: 20 had microalbumi-
nuria ACR 3–30 mg/mmol, group IV: 20 have macroalbu-
minuria ACR >30 mg/mmol.
Written informed consent was obtained from all par-
ticipants and the privacy of the data was considered.
Exclusion criteria included patients with liver diseases,
cardiovascular diseases, cancer, infections or inflammatory
conditions, renal disease other than diabetic nephropathy
and pregnancy. Patients and volunteers were fasted for at
least 6 hours and were asked to abstain from unaccus-
tomed physical activity for the preceding 24 hours. All
subjects rested for 30 minutes in a supine position prior
to initial blood sampling. All patients included in the
study were subjected to full history taking, complete clin-
ical examination (including blood pressure, fundus exa-
mination), ECG for exclusion of cardiovascular disease,
laboratory investigations included: glucose, HbA1c, renal
function tests, glomerular filtration rate by Cockcroft-Table 1 Demographic characteristics
Variable Group I Group II
Age 47.30 ± 4.63 51.36 ± 5.25
Gender M/F 6/4 8/2
Disease duration - 8.63 ± 3.25
M=male, F = female, * = significant.Gault Equation Creatinine clearance = { [140 - age (years)] ×
weight (kg)} / [72 × serum creatinine (mg/dl)] × (0.85 if
female), serum albumin, total proteins, Alanine amino-
transferase (ALT) and Aspartate aminotransferase (AST),
cholesterol levels and urine analysis that included: albu-
min concentration, urine creatinine and urinary concen-
trations of NAG. The kit uses a double antibody sandwich
enzyme Linked immunosorbent assay (ELISA). Catalog
No. MB 5700742.
Statistical analysis of the data of the present study was
conducted with SPSS Version 16 using the mean, stand-
ard deviation and Yates’ corrected chi-square test. One-
way ANOVA was used to compare means from all groups.
The relationship between urinary NAG and other para-
meters was determined using the Spearman correlation
analysis and the linear regression method. P values 0.05%
were considered to be statistically significant.
Results
Fifty diabetic patients were divided into three groups
according to albumiurea and 10 control subjects were
included in our study. No patient was excluded for any
reason. Demographic data were comparable between
groups while duration of the disease was significantly
longer in groups III and IV compared to group II (Table 1).
A total of 13 inpatients were enrolled in our study; 3 in
group II and 5 in each of group III and VI. They were ad-
mitted because of uncontrolled hyperglycemia (7 patients),
chest infection (6 patients).
HbA1C, albumin/creatinine ratio, serum creatinine
and serum urea showed statistically significant increase
in group IV compared to group III and group III com-
pared to group II and the all groups compared to group І
(Table 2).
Estimated GFR, serum cholesterol, urinary NAG showed
a statistical significant decrease in group IV compared to
group III and in group III compared to group II and in the
all groups compared to group І as showed (Table 2).
Significant positive correlation was observed between
urinary NAG and albumin/creatinine ratio (P = 0.006),
serum creatinine (P = 0.002) and HBA1C (P = 0.008)
(Figure 1).
Discussion
Our results revealed that there was significant increase
in HbA1c in (macroalbuminuric and microalbuminuric)Group III Group VI P
48.64 ± 5.74 52.84 ± 7.63 0.951
10/10 8/12 0.635
13.2 ± 4.63 12.4 ± 2.34 0.035*
Table 2 Laboratory and calculated data
Variable Group I Group II Group III Group VI P
HbA1C 5.10 ± 1.24 6.40 ± 2.42 7.86 ± 2.85 8.60 ± 3.17 0.006*
Albumin/creatinine ratio 1.53 ± 0.87 2.36 ± 0.95 21.69 ± 5.36 45.35 ± 13.25 0.001*
Serum creatinine mg/dl 0.75 ± 0.11 0.86 ± 0.13 1.60 ± 0.23 2.08 ± 0.63 0.008*
Serum urea mg/dl 32.14 ± 2.24 37.85 ± 5.64 55.96 ± 9.31 66.24 ± 10.24 0.002*
Estimated GFR ml/min 110 ± 25.36 93 ± 19.52 70 ± 15.49 56 ± 12.69 0.001*
Serum cholesterol mg/dl 180.6 ± 32.25 201.6 ± 29.60 214.9 ± 25.43 231.5 ± 29.6 0.020*
Urinary NAG ng/ml 0.93 ± 0.15 1.15 ± 0.25 1.33 ± 0.36 1.59 ± 0.42 0.001*
* = significant.
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tients and healthy controls) and this coincides with other
studies [9-13] that they recorded that Poor glycemic con-
trol is a well-known risk factor for most diabetic compli-
cations, not only diabetic nephropathy.
Comparison between all the studied groups as regard
Albumin/creatinine ratio, serum creatinine and serum
urea showed statistically significant increase in group IV
than group III and group III than group II and the all
groups than group І. This is agreement with the findings
of Mitsnefes et al. [14] who reported that higher levels
of blood urea and creatinine indicate a failing of GFR as
a result of decreased capability of the kidney to excrete
waste products. However, Devarajan [15] in chronic kid-
ney disease, found that blood urea will only be elevated
above the normal when more than 60% of kidney cells
are no longer functioning and the usefulness of blood
urea as an independent indicator or renal function is
limited the variability of its blood levels as a result of
non-renal factors such as gastro-intestinal hemorrhage,
mild dehydration, high protein diet and decrease perfu-
sion of the kidneys.
Our study revealed that eGFR was significantly lower
in diabetic patients than that of the healthy control
group, Similar findings were previously recorded by
others [16-20]. Moreover Jamal et al. [21] in their retro-
spective study to assess the factors affecting the prog-
ression of diabetic nephropathy and its complications,
they showed an average of 3.3 mL/year drop in GFR
and even greater among patients who reached ESRD
(5.9 mL/year) and the presence of persistent proteinuria
was a strong risk factor for subsequent loss of GFR so
they re-emphasizing earlier reports that established the
importance of sustained increases in urine albumin ex-
cretion in the pathogenesis and diagnosis of diabetic
kidney disease.
In this study, diabetic nephropathy was associated
with elevated urinary NAG values compared to a control
group. This increase in NAG was parallel to the severity
of renal involvement with a characteristic increasing
trend was observed among the three groups regarding
albuminuria. These results are in agreement with otherstudies [22,23] that stated that changes in urinary NAG
activity can reflect the activity of the disease as well as
the residual functional capacity of the kidney. Our re-
sults showed that even in the absence of any clinical
evidence of microvascular complications, urinary NAG
excretion was invariably elevated indicating that subclin-
ical renal tubular dysfunction may exist before the occur-
rence of glomerular damage. Kuzniar et al. [24] denoted
that in proteinuric glomerular diseases the increased NAG
excretion can occur even in absence of morphological
evidence of tubular cell damage, probably reflecting in-
creased lysosomal activity of these cells due to the in-
creased uptake of filtered proteins. Also Navarro et al.
[25] stated that NAG changes occur prior to microalbu-
minuria, probably because the tubular cells can reabsorb
the increased albumin load that results from glomerular
affection but the increased NAG will be lost from the
damaged cells. Also, Nauta et al. [26] showed that urine
NAG increases a surprising 9-fold in normoalbuminuric
patients with diabetes compared to controls. It increases
further with development and progress of microalbumi-
nuria. Moreover, in another study of diabetic patients,
Vaidya et al. [27] found, that urinary levels of tubular
injury biomarkers KIM-1 and NAG were significantly
elevated in patients with type 1 diabetes and macroal-
buminuria in comparison with diabetics with normoal-
buminuria and nondiabetic healthy controls. Low urinary
KIM-1 and NAG at baseline estimation were strongly as-
sociated with regression of MA during a 2-year follow-up.
It is generally agreed upon that there is some normally fil-
tered albumin that is reabsorbed by the proximal tubule.
If this reabsorption is impaired, we would expect to see
macroalbuminuria; therefore, the earliest kidney lesion in
type 1 DM may be tubular injury, not glomerular injury.
Also urinary NAG elevation would be expected to be en-
hanced with proximal tubule injury although it may also
be increased because of enhanced lysosomal activity with-
out injury. Also Kern et al. [28] showed the change in
NAG independently predicted macroalbuminuria. Thus,
the risk for macroalbuminuria raised more than two fold
for every 50% increase in urine NAG at baseline, and ad-
ditionally rose almost 9% for every unit increase in urine
Figure 1 Correlation between NAG and serum creatinine,
albumin/creatinine ratio and HBA1C.
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rence of macroalbuminuria. Moreover another study [29]
denoted that urinary NAG might be elevated in other dis-
eases other than diabetic nephropathy. They investigated
136 patients with primary glomerulonephritis [74 with
idiopathic membranous nephropathy (IMN), 44 with pri-
mary focal segmental glomerulosclerosis (FSGS) and 18
with minimal change disease (MCD)] they found Urinary
NAG excretion can be considered as a reliable marker of
the tubulo-toxicity of proteinuria in the early stage of
IMN, FSGS and MCD; the excretion values show a signifi-
cant relationship with 24-h proteinuria, Also Orfeas et al.
[30] found that patients in the highest urinary NAG had a
significantly higher prevalence of sepsis, higher Acute
Physiology and Chronic Health Evaluation (APACHE) II
score, Multiple Organ Failure (MOF) score, a higher likeli-
hood of mechanical ventilation, higher prevalence of
oliguria, and fractional excretion of sodium 1% as com-
pared with those with lower urinary NAG. Also Dialysis
requirement and hospital death were significantly higher
in the high urinary NAG level patient as compared with
the low urinary NAG level patient.
Correlation between Urinary NAG level and Albumin/
creatinine ratio, serum creatinine and HbA1c showed
significant + ve Correlation between Urinary NAG level
and all previous parameters , this coincides with Sato
et al. [31] stated that NAG total activity and A2 iso-
enzyme were highly correlated with the level of pro-
teinuria with A2/A1 ratio higher in glomerular diseases
(e.g. glomerulonephritis and diabetic nephropathy) than
tubulointerstitial pathologies (e.g. chronic pyelonephri-
tis and polycystic kidney). Also Abdelshakoer et al. [23]
showed that Urinary NAG was strongly affected by the
blood glucose control over the 1–7 days before urine
collection.
Our study is not without limitations. The number of
patients might be not enough to determine the reliability
and generalizability of urinary NAG levels as expressing
the degree of renal impairment in diabetic nephropathy.
Larger studies are needed to confirm or refute our results.
Also, our results remain limited to our patient population
in the fact that other factors than proteinuria may play a
role in the increased urinary NAG excretion in diabetics
like blood glucose control [32].Conclusion
Based on the limitations above, it can be concluded that
urinary NAG levels could be used as a useful biomarker
reflecting the degree of renal impairment in diabetic
nephropathy.
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